Adicet Bio (ACET)

• Market cap: $104M
• 1 day: -1.11%
• 5 days: 1.33%
• 1 month: -30.67%
• 3 months: -1.03%
• 6 months: 1.63%
• Year to date: -30.28%
• 1 year: -40.45%
• 5 years: -94.9%
• 10 years: -99.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152